Abbott LaboratoriesNYSE: ABT
Health Care · Health Care Equipment
$89.68
+1.14%
Vol: 2.5M
Research Digest
Tuesday, June 16, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14Abbott declared its 410th consecutive quarterly dividend amid a sharp YTD stock decline and product-approval momentum.Mixed▶
Abbott declared a quarterly dividend of $0.63 per share on June 12, 2026, marking its 410th consecutive quarterly payout since 1924. The stock is down roughly 17% over the past 90 days and about 31% YTD, pressured by reduced earnings guidance, nutrition-segment concerns, and competitive pressure, trading near $89.65. Offsetting the weakness, Abbott recently secured FDA and EU approvals for AI-driven stent-placement tools, glucose-ketone monitoring, the Volt PFA System for atrial fibrillation, and the Amplatzer Piccolo delivery system. CEO Robert Ford said on June 2 that healthcare demand will continue to accelerate. Analysts maintain a consensus near Strong Buy despite the drawdown. The gap between strong product flow and weak guidance is the key debate.
May 21Abbott closes $21B Exact Sciences acquisition for cancer diagnostics expansion despite ~$0.20 EPS dilution; Q1 beat lifts shares 3.18%.Mixed▶
Abbott closed its approximately $21 billion acquisition of Exact Sciences to expand its cancer diagnostics franchise. The deal is projected to cause short-term EPS dilution of $0.20 for fiscal 2026 due to integration costs. Despite this, Abbott beat Q1 2026 estimates with revenue of $11.16 billion and EPS of $1.15, with strong growth in diabetes care and medical devices. The company raised its full-year earnings guidance, sending shares up 3.18% to $87.16. The Established Pharmaceuticals Division reported 9% top-line growth. Abbott maintained a $0.63 mid-May quarterly dividend. Ongoing infant formula litigation remains a risk — a Missouri appeals court recently upheld a $495 million verdict, with over 1,700 additional lawsuits pending. Shares are down ~30.7% over the past six months but insider buying recently outpaced selling ($1.1M bought vs. $485K sold).
May 20Abbott trades around $88-$89 as analysts maintain Strong Buy despite 30.6% YTD decline tied to Exact Sciences dilution.Mixed▶
Abbott Laboratories shares fluctuated between $87.41 and $89.34 around May 19, 2026, with the stock still down 30.6% YTD following reduced guidance from its $21 billion Exact Sciences acquisition (closed March) that produced $0.20 in EPS dilution. Q1 adjusted EPS of $1.15 narrowly beat estimates and revenue grew 7.8%, but full-year EPS guidance was trimmed to $5.38-$5.58. Recent FDA approvals include the next-generation CardioMEMS remote heart failure monitor and the Volt pulsed field ablation system for atrial fibrillation. Insider buying by both the CEO (at $107) and CFO (at $91) is being interpreted as a confidence signal. Analyst consensus is Buy with an average price target of $118.64 (36.5% upside). Risk: a voluntary recall of certain 2 fl. oz. ready-to-feed liquid products and ongoing competitive pressures in medical devices.
May 19Abbott Laboratories rises 4.1% on May 18 on raised full-year guidance and Exact Sciences acquisition closePositive▶
Abbott Laboratories (ABT) shares jumped 4.1% on May 18, 2026 to $87.91 after beating Q1 2026 earnings driven by strong growth in diabetes care and medical devices segments and raising full-year guidance. The company closed its approximately $21B acquisition of Exact Sciences to expand cancer diagnostics, strengthening its market-leading oncology position. Abbott paid a mid-May quarterly dividend of $0.63 per share. Risk: Abbott faces a securities class action lawsuit alleging concealment of FDA health and safety violations at its infant formula facility, on top of a recently upheld $495M verdict and over 1,700 additional pending infant formula lawsuits creating significant legal exposure. Consensus Buy rating from 18 analysts as of May 6.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Abbott rises after Q1 beat but Goldman drops from Conviction List and securities class action lawsuit over infant formula deepensMixed▶
Abbott posted Q1 2026 revenue of $11.16B and EPS of $1.15, beating estimates with medical devices up 13.2% driven by FreeStyle Libre CGM. The stock rose 3.04% to $85.07 but remains down ~30% YTD on reduced guidance and competitive pressure. Goldman Sachs removed Abbott from its US Conviction List in May 2026 while Citi maintained Buy but trimmed price target to $136 from $140. A securities class action lawsuit alleges Abbott concealed FDA health and safety violations at its infant formula facility, compounding a recently upheld $495M baby formula verdict. Abbott declared a $0.63 quarterly dividend payable May 15, 2026. Risk: ongoing nutrition-segment litigation and dilution from Exact Sciences acquisition weighing on EPS.
May 14Abbott shares slip 2.1% on May 13 as Goldman Sachs removes stock from Conviction List and infant-formula securities class action deepens.Negative▶
On May 13, 2026, Abbott Laboratories shares declined 2.1% after Goldman Sachs removed the stock from its US Conviction List and Citi trimmed its price target to $136 from $140 while maintaining Buy. An ongoing securities class action lawsuit alleging Abbott concealed FDA health and safety violations at its infant formula facility continues to weigh on sentiment, after an Illinois jury recently awarded $70 million in damages tied to Similac Special Care and necrotizing enterocolitis cases. Abbott also received FDA clearance for its Ultreon 3.0 AI-enabled optical coherence tomography software intended for complex coronary stent procedures. The company's quarterly $0.63 dividend is payable May 15, 2026. ABT is down 30.6% YTD on reduced earnings guidance and Exact Sciences acquisition dilution. The key risk is that legal exposure from infant formula litigation and class action could continue to pressure guidance and the multiple.
May 13Abbott Laboratories director Daniel Starks bought 10,000 shares for $926,537 on May 2 amid a 15.9% monthly stock drop, with Q1 2026 revenue of $11.16B beating estimates.Mixed▶
Abbott outperformed Q1 2026 expectations with $11.16 billion revenue and $1.15 EPS. However, revised 2026 EPS outlook reflects dilution from the Exact Sciences acquisition and legal uncertainties in infant formula operations. On May 2, 2026, director Daniel J. Starks purchased 10,000 shares for $926,537, bringing his total holdings to 6.75 million shares. A quarterly dividend of $0.63 per share is payable May 15, 2026, extending Abbott's 54-year dividend streak. Analysts see the stock trading at a 27% discount to fair value with 9.1% projected annual EPS growth through 2028.
May 12Missouri appellate court upheld $495M verdict against Abbott on May 7 over preterm infant formula NEC injury, with Abbott now facing more than 1,700 similar lawsuits nationwide.Negative▶
A Missouri appellate court on May 7, 2026 upheld a $495M verdict against Abbott in a case alleging its specialty formula for premature infants caused necrotizing enterocolitis (NEC). Abbott now faces more than 1,700 similar lawsuits across the country, creating significant ongoing legal liability. ABT stock has fallen roughly 30% YTD to about $84.24 on May 8, also pressured by the dilutive impact of its $23B Exact Sciences acquisition that closed March 23. Abbott lowered full-year 2026 adjusted EPS guidance to $5.38-$5.58 from $5.55-$5.80 due to deal dilution. Q1 revenue of $11.16B and EPS of $1.15 beat estimates. Risk: NEC litigation overhang remains an open-ended liability.
May 11Abbott shares hit 52-week low after $495M baby formula verdict upheld and Erste Group cuts FY26 EPS forecastNegative▶
Abbott Laboratories shares slid to a 52-week low of $87.54 on May 4, 2026, amid lingering pressure from a $495 million baby formula verdict that was upheld by a court. On May 5, Erste Group Bank lowered its FY2026 EPS forecast for Abbott, adding to bearish sentiment. The stock is down roughly 29.81% year-to-date and 37% from its June 2025 high. Q1 2026 results posted in April showed revenue of $11.16B (up 7.8% YoY) and adjusted EPS of $1.15 in line with consensus, though operating margin compressed to 12% from 16.3%. Abbott also filed an update on May 7 for its BurstDR spinal cord stimulation trial in diabetic neuropathy.
May 8Wells Fargo reaffirms Buy rating on Abbott Laboratories as stock hits 52-week low of $86.15.Mixed▶
Abbott Laboratories stock hit a 52-week low at $86.15 as the company navigates legal challenges and stock price weakness despite solid Q1 revenue growth and strategic FDA approvals for new medical devices. The company reported 6% adjusted EPS growth and received approvals for CardioMEMS remote heart failure monitoring and Volt pulsed field ablation system. A Cook County jury awarded $70 million in damages ($53M + $17M) against Abbott in infant formula litigation. Wells Fargo maintained its Buy rating as of May 6, 2026. Risk: ongoing legal exposure from infant formula lawsuits could dampen sentiment despite strong medical device innovation.
May 6Abbott reports Q1 revenue beat, gains FDA approvals for AI-powered imaging and monitoring devicesPositive▶
Abbott reported Q1 2026 revenue of $11.16 billion (up 7.8% YoY) beating estimates of $11.03 billion. Adjusted EPS grew 6% YoY. Company received FDA clearance for Ultreon 3.0 AI-powered imaging system, CardioMEMS remote heart failure monitoring reader, and Volt pulsed field ablation system for atrial fibrillation. Despite solid fundamentals, stock declined 37.1% from 52-week high ($139.06 to $87.54), trading near lows. Insiders are accumulating shares. Analyst consensus: Strong Buy with average price target of $119.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABTABBOTT | $89.68 | +1.14% | +0.9% | 14.6x | 0.62 | $154.4B |
| ISRGINTUITIVE | $419.37 | +0.68% | -5.3% | 35.3x | 1.45 | $147.5B |
| SYKSTRYKER | $308.10 | +0.05% | -1.7% | 18.4x | 0.79 | $118.1B |
| MDTMEDTRONIC | $80.86 | +0.60% | +4.0% | 12.6x | 0.60 | $103.2B |
| BSXBOSTON | $46.69 | -0.16% | -16.4% | 12.6x | 0.56 | $69.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.